Podcasts about clinicians

Eating disorders in the military are far more common than most people realize, yet the signs and symptoms often go unnoticed until the consequences become severe. In this eye-opening episode, retired Navy Senior Chief, author, and SEA WAVES founder Leah Stiles shares her lived experience with an eating disorder, including the challenges she faced seeking help. She explains how military culture can contribute to the development of eating disorders, and why so many service members struggle in silence. We discuss the impact on active-duty military members, veterans, and military families, as well as what clinicians, leaders, loved ones, and policymakers can do to better recognize and support those who are struggling. Tune in for a powerful conversation about breaking stigma, saving lives, and shining a light on a hidden crisis.   If you or someone you care about is an athlete in recovery, this episode will make your recovery journey a little more hopeful.   If you enjoy our show, please rate, review, subscribe, and tell your friends and colleagues!   Interested in being a guest on All Bodies. All Foods.? Email podcast@renfrewcenter.com for a chance to be featured.   All Bodies. All Foods. is a podcast by The Renfrew Center. Visit us at: https://renfrewcenter.com/

Send us Fan MailThe calls that keep coming back aren't always “police problems” they're often people problems that never got solved. I'm joined by Amanda Rizzoli, clinical program coordinator with Milford Police Department in Massachusetts' Family Services Unit and Community Impact, plus Detective Cody Carneiro, to pull back the curtain on what a Family Services Unit actually does day to day and why it can change outcomes for families and first responders alike.We talk about the “merry-go-round” every officer knows: the same address, the same conflict, the same crisis, and the same short-term fix. Amanda and Cody explain how the unit focuses on root-cause work across mental health, substance use, domestic violence, runaway youth, and family instability. That means connecting people to the right behavioral health care, outpatient therapy, case management, housing applications, shelter options, and ongoing follow-up so a single incident doesn't turn into a pattern.We also get into the bigger picture of community-based policing and co-response models: how school-based relationships help kids feel safe reaching out, how clinicians and officers support each other on tough scenes, and how partnerships like Community Impact and Chris's Corner create real options when a town is trying to help someone who is homeless or stuck in a revolving door of crisis calls.Then we go where it matters most: first responder mental health stigma. We talk candidly about the fear of being seen as weak, the worry about fit-for-duty judgments, and why leadership support can make or break whether people get help. If you've ever wondered what actually works to move a “ten years on” veteran toward support, we share the simplest answer: start with a real conversation and make mental health a normal checkup, not a career risk.Support the showYouTube Channel For The Podcast

The Nurses Report on America Out Loud with Gail Macrae, BSN, RN – The larger system, she argues, is not designed to change itself but to make profit—at what cost? Attempts to bring rigorous, data-driven reform into federal agencies have been blocked at every turn. The financial incentives around liability-free products and continuous pharmaceutical development remain intact...

Are we addressing sexual health in clinical practice? On this episode of BackTable Women's Health, host Dr. Nicole Faulkner is joined by Dr. Christine Vaccaro, a double board-certified urogynecologist and sexual medicine specialist, to discuss the evaluation and care of women's sexual health concerns. They highlight the importance of open conversations, patient empowerment, and a multidisciplinary approach to support well-being and improve quality of life. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction04:01 - What Is Sexual Medicine07:58 - Understanding Libido, Arousal, and GSM15:54 - Clinic Visit Structure and Patient Counseling19:17 - Clitoral Exam, Adhesions, and Anatomy Education28:17 - Addressing Stigma, Patient Education, and Myths32:03 - Tools for Patient Empowerment: Apps and Self-Examination39:55 - In-Office Procedures, Pain Mapping, and Hormonal Considerations46:37 - Managing Complex Cases and Multidisciplinary Collaboration53:47 - Closing Remarks --- More about this episode The conversation explores practical strategies for evaluating and managing issues such as libido, arousal, orgasm, and sexual pain, with a focus on genitourinary syndrome of menopause (GSM) and clitoral anatomy. Dr. Vaccaro shares her approach to assessing clitoral adhesions, pelvic pain, and hormonal changes, as well as effective ways to educate patients about anatomy and self-examination. They discuss the importance of reducing stigma, addressing misconceptions, and using a multidisciplinary approach to improve patient outcomes. The episode also highlights the role of clinician training, patient-centered counseling, and collaborative care in supporting women's sexual health across the lifespan. --- Resources International Society for the Study of Women's Sexual Health: https://www.isswsh.org/ Female Orgasmic Disorder: Current Understanding and Clinical Management: https://pubmed.ncbi.nlm.nih.gov/42314165/ OMGyes: https://www.omgyes.com/join You Are Not Broken by Dr. Kelly Casperson: https://kellycaspersonmd.com/you-are-not-broken-book/ Retrospective Study of the Prevalence and Risk Factors of Clitoral Adhesions: Women's Health Providers Should Routinely Examine the Glans Clitoris - https://academic.oup.com/smoa/article/6/2/115/6956478?login=false Clitoral Adhesiolysis: Technique and Patient Selection - https://www.vjsm.info/videos/all/clitoral-adhesiolysis-technique-and-patient-selection Female Orgasmic Disorder: Current Understanding and Clinical Management - https://pubmed.ncbi.nlm.nih.gov/42314165/ --- BackTable Women's Health is the go-to podcast for gynecologists, gynecologic surgeons, and other healthcare professionals focused on women's health. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

About 30% to 40% of the world's population is affected by some form of allergic disease, making allergy a routine consideration in primary care. But as interest in the microbiome grows, clinicians and patients face an important question: what does the evidence actually tell us about its role in allergic disease? This episode explores immune development, the hygiene and biodiversity hypotheses, food allergy, early-life tolerance, the gut-skin axis, atopic dermatitis, asthma, allergic rhinitis, antibiotic exposure, diagnostic testing, and early peanut introduction. The discussion separates established evidence from emerging associations and considers what, if anything, should change in clinical practice today. Clinicians will come away with practical guidance on maintaining evidence-based allergy diagnosis and management while understanding where microbiome research may shape future approaches to prevention and care. Resources and references: https://www.thermofisher.com/phadia/us/en/resources/immunocast/microbiome-and-allergy-what-primary-care-should-know.html?cid=0ct_3pc_05032024_9SGOV4

Is your practice website actually helping patients choose you, or is it just a digital brochure listing your services? In this episode, Dr. Lauryn sits down with branding strategist Alexa Torres to unpack what makes a healthcare brand connect, convert, and stand out in 2026. They explore why great marketing starts with making patients feel seen, not simply telling them how qualified you are.Alexa breaks down emotional selling, identifying your primary audience, creating a website that functions like a pre sales conversation, and designing for both quick decision makers and analytical buyers. They also dive into using AI to develop your brand voice, write better content, build websites, and even create an AI twin that helps you show up consistently without constantly being on camera.Key TakeawaysPatients buy outcomes, not services. Effective healthcare marketing speaks to the emotional problem behind what a patient is experiencing so they immediately recognize that your practice understands them.Your website should operate like a sales conversation. Strategic messaging, clear positioning, intentional calls to action, and a series of small “yeses” can pre sell prospective patients before they ever contact your practice.Your personal brand matters, but your patient should remain the focus. Establish your expertise and personality without making the homepage a résumé about your education, credentials, and accomplishments.AI works best when you give it your ideas instead of asking it to invent them. Detailed prompting, voice training, AI assisted website building, and tools like AI twins can make marketing faster while still preserving the perspective that makes your brand unique.Guest BioAlexa Torres is a creative director and branding strategist who has built more than 200 brands and websites since beginning her career in 2009. After shifting her focus exclusively to healthcare in 2016, Alexa and her team have helped more than 100 health entrepreneurs transform their ideas into magnetic brands that attract ideal patients, communicate their value clearly, and inspire action. Through her branding agency, Care Identity, and educational platform, The Clinician's Atelier, she helps healthcare entrepreneurs strengthen their branding, websites, messaging, and marketing while leveraging emerging AI tools to work more efficiently.For ways to work with Alexa, visit The Kliˈnishen's AtelierFollow Alexa on InstagramResources:Find all things Dr. Lauryn B including ways to work with herFollow Dr. Lauryn: Instagram | Facebook | LinkedInFollow She Slays on YouTubeMentioned in this episode:INSiGHT CLAThis episode is brought to you by the INSiGHT scanning system from CLA, the tool that helps chiropractors show patients objective neurological data so the value of care becomes clear, fueling conversion, retention, and growth. She Slays listeners get preferred pricing, affordable financing, and a free Getting Into Scanning guide.CLA (Current)Holistic Marketing HubThis episode is sponsored by Holistic Marketing Hub. Created by marketing strategist Molly Cahill, it's a proven Instagram system with a 500+ caption content library and a step-by-step curriculum that's helped 400+ chiropractors, acupuncturists, and other health pros fill their practices with right-fit patients. Enroll Now!Holistic Marketing HubClinic MindClinic Mind is the all-in-one EHR and practice management platform built for chiropractors — billing, documentation, scheduling, and patient follow-up in one place, whether you run a cash practice, take insurance, or are scaling to multiple locations. She Slays the Day listeners get an exclusive offer.Clinic Mind

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, delivers a solo “Spilling the Tea” segment exploring clinical observations that may warrant a closer look. He examines dermatomyositis findings that can mimic more common conditions, nuances in prescribing language, the importance of a thorough hidradenitis suppurativa (HS) examination, and an unexpected case of rhabdomyolysis, highlighting details that can change how clinicians approach diagnosis and patient management. Dr Del Rosso begins with scalp pruritus as a potential manifestation of dermatomyositis. He reviews images showing how scalp involvement may resemble seborrheic dermatitis or psoriasis, with findings such as erythema, scaling, and hair thinning. He also examines nailfold changes, including prominent capillaries, capillary dropout, and abnormal cuticles, that can provide additional diagnostic clues. Recognizing these findings is particularly important given the potential systemic implications of dermatomyositis. The discussion then turns to limitations of use in prescribing information stating that certain therapies are “not recommended” in combination with other agents. Dr Del Rosso distinguishes this language from a formal contraindication and discusses the importance of understanding the evidence behind labeling when making treatment decisions. In HS, he emphasizes the value of a complete skin examination, including areas patients may initially be reluctant to expose. Assessing and palpating lesions can help distinguish active inflammatory findings, including abscesses, nodules, and draining tunnels, from established fibrotic or scarred disease. Finally, Dr Del Rosso shares the case of a 42-year-old woman receiving JAK inhibitor therapy who developed markedly elevated creatine kinase and rhabdomyolysis. Although her medication presented one possible explanation, further investigation revealed that she had gone several weeks without levothyroxine for hypothyroidism, another potential contributor. The case illustrates the importance of considering the full clinical picture when evaluating an unexpected finding or adverse event. Tune in to the episode for clinical observations that encourage a closer look at what may initially seem straightforward, from recognizing less familiar disease presentations and interpreting prescribing information precisely to conducting a thorough examination and considering multiple explanations for an unexpected finding.

Uncage Your Income: 5 Ways Clinicians Can Create Passive Income What if you could make more money without simply adding more patients, more hours, or more stress to your schedule? In this episode of the Uncaged Clinician Podcast, David Bailiff is joined by Santi Villamil, the "Physio Sensei," to talk about one of the biggest challenges facing physical therapists and healthcare professionals today: how to stop trading all of your time for money. After years of working inside traditional healthcare systems, Santi shares how he learned to think differently about compensation, business, relationships, and the way he serves his clients. David and Santi break down practical ways clinicians can create additional income while building a business that gives them more freedom, flexibility, and time. You'll hear five outside-the-box strategies, including: Creating affiliate relationships and earning income from products you already recommend Turning treatments, protocols, resources, and memberships into scalable offers Renting unused clinic space to complementary healthcare and wellness providers Creating recurring revenue through monthly memberships and office hours Thinking differently about how you get paid and considering alternative forms of compensation But this conversation goes far beyond passive income. David and Santi challenge clinicians to move away from a scarcity and competition mindset and toward collaboration, relationships, abundance, and serving the client first. They discuss why building relationships with other professionals can create both referrals and new revenue opportunities—and why your business doesn't have to follow the traditional healthcare playbook. If you're a physical therapist, healthcare professional, clinic owner, or clinician who feels stuck trading time for money, this episode will challenge you to think differently and do differently. It's time to uncage your mind, uncage your business, and create a career that gives you more freedom—not more burnout. Listen in and discover how you can start thinking uncaged today.

In this practical Q&A episode with Dr. Jonathan Shedler, the psychodynamic psychotherapy cohort explores working with transference in real time, focusing on timing, technique, and the here-and-now. Shedler addresses how to recognize meaningful transference patterns, decide when an interpretation will open growth versus overwhelm the patient, and adapt the work across levels of personality organization (neurotic versus borderline). The discussion covers handling negative and erotic transference, protecting the therapeutic frame, triangulation, idealization and splitting, devaluation, projection, and projective identification. Clinicians will also learn to use their own countertransference as essential clinical data, the ongoing value of consultation and supervision, and how to respond to chronic reassurance-seeking without colluding.   Link to blog Link to YouTube video

CardioNerds (Dr. Apoorva Gangavelli, Dr. Cory Sejo, and Dr. Joseph Kassab), discuss tricuspid regurgitation evaluation and management with Dr. Sunil Mankad. This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course.  Audio editing by CardioNerds intern Emma Winakur. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Key Points: Tricuspid regurgitation is common and associated with increased mortality at every stage, regardless of etiology. Outcomes are worse with worsening severity, so accurate grading is critical. Etiology is critical to guide treatment decisions. Etiology includes primary vs secondary (atrial or ventricular) vs CIED-related TR. 3D echocardiography can be very helpful in determining TR etiology, especially in CIED-related TR. Diuresis with the goal of euvolemia is step one. Additionally, underlying contributory conditions (eg. pulmonary HTN, HFrEF, atrial fibrillation) should be addressed, if appropriate, and then TR severity reassessed. The choice between T-TEER and TTVR hinges on anatomy, RV function, pulmonary hypertension, and the ability to tolerate anticoagulation. T-TEER is generally first line in atrial functional TR with appropriate anatomy, in patients with poor RV function who cannot tolerate a sudden increase in RV afterload, or in patients who cannot tolerate the necessary anticoagulation with TTVR. TTVR is preferred with wide coaptation gaps and CIED-related TR. This is a team sport. Multidisciplinary discussions utilizing imaging (TTE/TEE, CT), risk scores (TRI-SCORE or TRIO), patient preference, and prior institutional experience are essential for the effective treatment of severe TR. Notes: What is the clinical importance of tricuspid regurgitation? TR is very common with approximately 4% of people over 75 having moderate or greater severity. TR (even mild) is associated with increased mortality. Those outcomes worsen as the TR severity worsens, and this phenomenon is independent of the mechanism of regurgitation. What is unique about the tricuspid valve compared to the other cardiac valves? It is at an anterior location which allows it to be imaged well with transthoracic echocardiography It is the largest valve and composed generally of 3 leaflets (but very often can have 4+ leaflets). Importantly, the RV is compliant and changes size and shape readily based on loading conditions. The TV annulus similarly changes size and shape based on hemodynamic conditions such as preload. What is a good framework for approaching the causes of tricuspid regurgitation? Determine the presence and define the severity of TR. Using TTE, we want to measure the right atrial size, the RV size, and any other concomitant valvular lesions.  Use TTE (2D and 3D) to characterize leaflet anatomy and characteristics. Subtypes of TR mechanisms (many times etiology is mixed). Primary: primary leaflet abnormality, occurs in ~10% of cases. Look for prolapse, flail, endocarditis, etc. Secondary/functional: leaflets normal but surrounding structures are abnormal. Atrial: RA and tricuspid annular dilation but normal RV size/shape, and can be related to arrhythmias like atrial fibrillation. Ventricular: RV dilated and/or dysfunctional with leaflet tethering. Can be related to pulmonary hypertension or primary RV disease. Cardiac implantable electronic device (CIED): Related to device (usually pacemakers or ICD) interaction with TV leaflets. Includes perforation, entanglement in subvalvular apparatus, impingement, etc. 3D TTE particularly helpful to evaluate How do we grade TR severity? It is very important to grade the severity of TR, and this is generally done with echocardiography. There are both quantitative and qualitative methods which use Doppler and various equations to estimate TR severity. Current recommendations have expanded TR severity beyond mild/moderate/severe to include “massive” and “torrential” categories. The most important parameters measured/calculated are vena contracta width, regurgitant volume, regurgitant fraction, and effective regurgitant orifice area. Helpful qualitative metrics include hepatic venous flow reversal. When should additional studies beyond transthoracic echocardiography, such as transesophageal echocardiography (TEE), cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI) be pursued? TEE is particularly helpful if TTE views are poor. Since TEE is used during transcatheter intervention, a pre-procedure TEE to define anatomy, determine procedure candidacy, and plan for the procedure is critical.  CT is also helpful for procedure planning and has particular strengths in defining annulus size and geometry. A CT is required prior to transcatheter tricuspid valve replacement (TTVR). MRI is helpful for measuring RV volumes and function, but is not generally used to assess TR severity.  What is the approach to the treatment for severe tricuspid regurgitation? The first step is to try to determine the etiology. For secondary TR, treating the underlying condition is indicated. For example, pulmonary vasodilators for pulmonary HTN or guideline therapy for heart failure with reduced ejection fraction. Diuretics are the mainstay for treatment, with the goal to obtain euvolemia. This may require inpatient admission to optimize volume status and medication regimen. Once reversible etiologies are addressed, if the patient is still symptomatic from TR, additional therapies can be considered. What is the role of right heart catheterizations (RHC) in patients with severe TR? RHC is very helpful for many reasons. We use it in TR to help determine volume status, cardiac output, and RV function. Additionally, identifying and characterizing pulmonary hypertension (with pulmonary artery pressures and calculating pulmonary vascular resistance) is an important factor when choosing future therapies.  With severe tricuspid regurgitation, when should we refer for intervention (either with surgery or transcatheter repair or replacement)? Once reversible etiologies are addressed and euvolemia has been achieved, if the patient is still symptomatic from TR despite aggressive medical optimization, additional therapies can be considered. Once euvolemic, a repeat TTE should be ordered to reassess the severity of the TR. Use calculators (for example, either the TRI-SCORE or TRIO score) to predict operative mortality for isolated TR surgery. What are our transcatheter treatment options in severe tricuspid regurgitation, and how do we choose between them? The primary approved transcatheter treatment options for severe TR include transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), of which the Edwards EVOQUE valve is the only one currently approved by the FDA. There are other TTVR device under investigation. These decisions should be made with a multi-disciplinary team including representation from cardiac imaging, interventional cardiology, and cardiothoracic surgery. Factors that go into the decision between T-TEER and TTVR include anatomy (annulus width, coaptation gap, leaflet length), RV reserve, pulmonary hypertension presence, ability to tolerate anticoagulation, patient preference, and institutional experience.  T-TEER is generally the first line with atrial functional and suitable anatomy. It is successful at reducing TR but does not generally eliminate it.  TTVR with EVOQUE is preferred in certain anatomic considerations like a large coaptation gap or when there is CIED-related TR (as this was excluded in T-TEER trials). Patients must be suitable for anticoagulation to receive TTVR as there is risk of leaflet thrombosis without it. If moderate/severe pulmonary hypertension is present, or there is poor RV function, TTVR may be avoided as the sudden elimination of TR causes a sudden increase in RV afterload which may not be tolerated. What is the role in advanced metrics for evaluating RV function? Advanced metrics like RV/PA coupling are under investigation but have not made it into the guidelines. The clinical utility is not yet known.  Assessing the RV function is important as stated above. Dr. Mankad prefers using 3D TTE to calculate an RVEF, or tracking RV longitudinal free wall strain. If you do encounter CIED-related TR, how do you treat it? Evaluate with TTE or TEE. 3D is very helpful to identify relative anatomy and leaflet-device interactions. There is no clear consensus about treatment if CIED-related TR is the primary mechanism of severe TR. If recently implanted, repositioning may be a valid option, but requires discussions with multiple teams including electrophysiology, advanced cardiac imaging, CT surgery, and interventional cardiology. References O’Gara PT, Lindenfeld J, Hahn RT, et al. 10 Issues for the Clinician in Tricuspid Regurgitation Evaluation and Management: 2025 ACC Expert Consensus Decision Pathway. J Am Coll Cardiol. 2025;S0735-1097(25)07047-0. O’Gara PT, Little SH, Badhwar V, et al. Operator and Institutional Recommendations and Requirements for Tricuspid Interventions: 2026 ACC/AHA/ASE/HRS/STS Expert Consensus Systems of Care Document. J Am Coll Cardiol. 2026;S0735-1097(26)05481-1. Hahn RT. Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1876-1891. Davidson LJ, Tang GHL, Ho EC, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation. 2024;149(22):e1223-e1238.

What if the first clinician you hire isn't as good as you?It's one of the biggest fears we hear from successful solopreneurs—and it's exactly what Nicole struggled with when we started growing PelvicSanity.Because hiring your first clinician isn't just adding another person to the schedule.It's changing your entire role.Suddenly, you have to trust someone else with your patients, your reputation, your culture and something you've worked incredibly hard to build.And yes...Nicole struggled with this enough that she eventually went to therapy to work through some of the control issues that came with becoming a leader.

Thinking about exporting your MedTech product to the GCC? What if finding a great distributor is only the beginning of what you need to succeed?The GCC can be an attractive export market for MedTech companies, but you can't simply take the strategy that worked in the UK, Europe or US, appoint a distributor and expect the same results. In this episode, Hakeem speaks with GCC MedTech distributor Sameh Salama about what manufacturers need to understand before entering the region, from choosing the right commercial partner and navigating local purchasing dynamics to clinical education, KOL engagement and supporting your distributor after launch. By listening you'll discover:Why the GCC isn't one MedTech market and what manufacturers need to understand before choosing where and how to enter. How to choose a distributor with the right portfolio, relationships and capacity to successfully commercialise your MedTech product. Why successful MedTech export requires an ongoing partnership between manufacturer and distributor, including clinical education, training, market development and clear activity plans that lead to sales. Listen now to learn how to commercialise and export your MedTech product successfully in the GCC by choosing the right partner, supporting them effectively and building the market for long-term adoption and growth.Book a 30min Healthcare Export Accelerator discovery callMessage me via DM on LinkedinThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.

Dr. Austin Chiang has built one of medicine's most distinctive public platforms. He is a triple board-certified gastroenterologist, Chief Medical Officer for Medtronic's Endoscopy business and Associate Professor of Medicine at Thomas Jefferson University. He is also one of healthcare's most influential physician voices online, with hundreds of thousands of followers across TikTok, Instagram, YouTube and LinkedIn. That makes him an ideal guest for Season 11 of Fixing Healthcare with cohosts Dr. Robert Pearl and Jeremy Corr. This season asks what patients, clinicians and healthcare leaders are saying now that feels meaningfully different from the past. Chiang hears those concerns from several vantage points: as a practicing physician, medical technology leader, educator and public-facing doctor. For Chiang, three issues stand out: Clinician burnout and loss of autonomy Chiang says physicians are struggling with administrative burden, documentation demands, prior authorization, staffing shortages, reimbursement pressure and a growing sense that medical decisions are no longer fully in their hands. Pearl pushes further, asking whether clinicians must take more responsibility for affordability rather than simply objecting to the oversight created in response to rising costs. Chiang agrees that physicians need a better understanding of the broader healthcare ecosystem if they want to help change it. Medical misinformation and social media Chiang has spent more than a decade learning how to communicate across platforms and audiences. He explains that accurate medical information must now compete with sensationalized claims from people who are not held to the same professional standards as clinicians. For doctors, the challenge is to be credible without being boring, engaging without becoming irresponsible and platform-specific without compromising the message. That tension is especially important in areas like gut health, diet, probiotics and the microbiome, where uncertainty creates space for simple but potentially misleading answers. Clinician-led innovation As Medtronic's Chief Medical Officer for Endoscopy, Chiang works at the intersection of clinical practice and medical technology. He explains that innovation in medicine is slow for good reason: new tools must prove safety, clinical value, workflow fit and real-world usefulness before becoming mainstream. But he argues that clinicians need to be more involved in that process because they understand the nuances of patient care, staff experience and adoption better than outsiders can. The conversation also explores colorectal cancer, which is rising among younger adults. Chiang explains why colonoscopy remains the gold standard for prevention, while also noting that lowering screening ages further would create major capacity challenges. He also discusses AI-assisted polyp detection, the future of endoscopy and why fully autonomous colonoscopy remains difficult given the complexity of human anatomy. There's much more in this conversation, including physician career paths beyond traditional practice, how doctors should respond when patients bring AI-generated information to appointments and what people with chronic GI conditions need from clinicians, platforms and online communities. Tune in to hear one of medicine's most visible digital physician leaders explain how doctors can help shape a future where technology, social media and medical innovation better serve patients. * * * Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify, Stitcher or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post FHC #224: Austin Chiang on burnout, misinformation and the future of med-tech appeared first on Fixing Healthcare.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

In this episode of PsychopharmaPearls, Dr. Andy Cutler and Dr. Will Sauvé discuss what clinicians need to know about kratom. They review why patients use it, signs of misuse, dependence, or withdrawal, and key pharmacologic and safety concerns. The conversation also offers practical guidance for discussing kratom use and incorporating it into treatment planning.  William Sauvé, MD, is a board-certified psychiatrist and Chief Medical Officer at Osmind. He has extensive experience in interventional psychiatry, including TMS and esketamine, and previously served for 11 years as an active-duty Navy psychiatrist. He also serves on the faculty of the Neuroscience Education Institute.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress  Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!

Medical screening is often framed as an uncomplicated good: if disease is found earlier, treatment can begin earlier and outcomes should improve. This episode examines why that reasoning is incomplete. Screening can produce benefit, but it can also generate false positives, incidental findings, overdiagnosis, overtreatment and diagnostic cascades. Dr. Austin Baraki discusses the distinction between screening people without relevant symptoms and investigating a clinical problem, the probabilistic interpretation of test results, biases that can make screening appear more effective than it is, and the importance of shared decision-making before a test is ordered. Timestamps: [03:35] What screening means [06:36] Choosing what to screen [11:59] Sensitivity and specificity [16:54] Predictive value and prevalence [22:16] Harms of screening and testing [31:02] Overdiagnosis and biases [41:40] The $50,000 physical [44:49] Overdiagnosis vs false positives [53:03] Overtreatment and surveillance [57:22] Clinician action bias [01:02:30] What to screen for Links: Go to episode page (with resources) Join the Sigma newsletter for free Subscribe to Sigma Nutrition Premium Enroll in the next cohort of our Applied Nutrition Literacy course Instagram: @austin_barbellmedicine Twitter: @AustinBaraki

If your MedTech product isn't selling as quickly as expected, are more salespeople really going to fix the problem?When a MedTech launch underperforms, hiring more salespeople, recruiting another distributor or attending more exhibitions can feel like the obvious answer. But if the market hasn't been prepared and customers don't yet see a compelling reason to change, more sales activity won't solve the underlying problem. In this episode, Hakeem explains why successful MedTech commercialisation and export starts long before launch—and why understanding and preparing your market can save you from trying to force adoption later.In this episode you'll discover:Why MedTech commercialisation should begin months before your product launches, rather than after regulatory approval.Why adding salespeople or export distributors won't fix a market that isn't ready to adopt your product.How understanding what keeps your customers awake at night can help you create demand, prepare the market and accelerate adoption.ActionListen now to learn how to prepare your market before you commercialise or export your MedTech product, so your sales team can convert demand rather than having to create it from scratch.Book a 30min Healthcare Export Accelerator discovery callMessage me via DM on LinkedinThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.

Clinicians can spend less time documenting care and navigating charts when AI is built directly into their workflow. In the latest episode of the athenahealth podcast, we introduce the athenaAmbient and AI-native encounter open betas. We go in-depth on the two experiences, what customers can expect during rollout, and how they can prepare – and share how customer feedback will help shape these capabilities as access expands.

Clinicians and medical providers rely on data to tailor care plans to their patients. Aartik Sarma, MD, University of California, San Francisco, Pat Lyons, MD, Oregon Health & Science University, and host Lekshmi Santhosh, MD, the University of California, San Francisco, discuss the use of data science in critical care medicine and how it has evolved over time. They dive into how new technologies benefit ICU patients, and how the medical infrastructure can be further improved.

Four years in, and we're going back to basics.In this episode of Breaking the Rules, Celin and Tori walk through the full OCD assessment process from the ground up - because with new listeners joining and so much focus on treatment in recent episodes, it felt like the right time to start at the beginning.How do you actually assess for OCD? What does a comprehensive clinical interview look like? When do you bring in psychometrics? And what happens when the OCD isn't responding to ERP the way it should?Celine and Tori cover the full assessment process — from taking a developmental history to using the Y-BOCS, working through the DSM-5 criteria, and navigating differential diagnosis. They also discuss PANDAS and PANS: the rare but important condition where OCD is triggered by an infection, why ERP alone won't work, and how asking one simple question about recent illness can completely change a treatment pathway.Whether you're a clinician new to the OCD space, refreshing the fundamentals, or someone who's wondered how OCD gets diagnosed — this one's for you.In this episode, you'll learn:Why a full developmental history is non-negotiable — even with adult clientsThe two age of onset clusters for OCD and why they matterHow to use the Y-BOCS as an interview tool rather than a take-home questionnaireWhy scoring the Y-BOCS isn't enough — and what you still need to checkJonathan Grayson's Freedom from OCD scale as an alternative for clinicians new to the spaceThe DSM-5 criteria for OCD explained in plain languageHow to differentiate OCD from anxiety disorders, autism, OCPD, and other co-occurring conditionsWhat the insight specifier really means — and why good insight doesn't mean mild OCDWhat PANDAS and PANS are, how to spot them, and why they require medical treatment firstHow a thorough assessment sets you up seamlessly for ERPAlso featuring: a baby learning to roll over in the background.www.melbournewellbeinggroup.com.au Hosted on Acast. See acast.com/privacy for more information.

In this episode, host Alyssa Watson, DVM, welcomes Claire Tucker, DVM, MPH, PhD, DACVECC, and Kelly Hall, DVM, MS, DACVECC, to discuss their recent Clinician's Brief article, “Projectile Injury in Dogs.”  Like with all trauma cases, Dr. Tucker and Dr. Hall lay out the systematic approach that is ideal for these injured pets and share some particulars for recognizing and handling projectile wounds. They also emphasize the importance and process of client communication for sudden, life-threatening problems. Resources: https://www.cliniciansbrief.com/article/gunshot-wounds-projectile-injury-dogs https://www.zoetisus.com/petcare/care-is-your-calling/ Contact: podcast@instinct.vet Where To Find Us: Website: CliniciansBrief.com/Podcasts YouTube: Youtube.com/@clinicians_brief Facebook: Facebook.com/CliniciansBrief LinkedIn: LinkedIn.com/showcase/CliniciansBrief/ Instagram: @Clinicians.Brief X: @CliniciansBrief The Team: Alyssa Watson, DVM - Host Alexis Ussery - Producer & Multimedia Specialist

What if the biggest thing standing between your client and better health isn't the protocol, but what they believe about themselves? In this episode of the IRH Clinician's Corner, Margaret Floyd Barry is joined by IRH staff member Ishbel Cavaleri to explore the pivotal role of mindset and self-belief in achieving lasting health transformations. We'll explore why simply providing protocols isn't enough, how to help clients become the heroes of their own stories, strategies to support change when it feels overwhelming, and ways practitioners can avoid common mistakes like taking setbacks personally or moving into "fix-it" mode. This episode is packed with practical tools and powerful reframes for clinicians and anyone striving to make sustainable health changes.  Inside this episode, we explore: Why client agency, not practitioner perfection, drives lasting change How to uncover a client's deeper "North Star" beyond symptom relief Why tracking progress helps clients build evidence that change is working How temporal discounting can derail even highly motivated clients Why setbacks should be expected and normalized, not treated as failure How identity and self-talk shape a client's ability to follow through on a protocol The Clinician's Corner is brought to you by the Institute of Restorative Health: https://instituteofrestorativehealth.com/ Connect with IRH: Upcoming Event: PCOS has a new official name: Polyendocrine Metabolic Ovarian Syndrome. The science isn't new. Functional practitioners have understood the metabolic and hormonal complexity of these cases for years. The name just finally says so. On August 12th, Margaret Floyd Barry and Sara Fields are hosting a free live session on what this means for your practice. What shifts in how you assess and talk with female clients. What stays the same. Live Q&A at the end. Free. 60 minutes. Register here! Follow us on IG: https://www.instagram.com/instituteofrestorativehealth/ Join our email list here: https://instituteofrestorativehealth.com/join-our-email-list/ Connect with Ishbel Cavaleri: Website: https://gutsyhormone.com/ Instagram: https://www.instagram.com/gutsyhormone/ Facebook: https://www.facebook.com/IshbelWELL Timestamps: 00:00 Diet change impacts relationships 08:09 Balancing health and family priorities 15:52 Discussing mindset and habit formation 18:00 Building healthier habits anytime 26:45 Resisting the urge to advise 33:32 Creating a bridge with healthier desserts 35:38 Impact of Social Circles on Lifestyle 41:11 Identity shift through dietary change 45:29 Challenging year with clients 50:54 Dealing with client criticism 56:13 Preparing clients for tough moments 01:03:28 Link between physiology and thoughts 01:10:24 Discussing the hormones course Guest bio:    Keywords: functional health practitioners, mindset and belief in health, client self-sabotage, tracking client progress, health behavior change, North Star motivation, symptom-driven motivation, chronic disease reversal, client journaling, nutrition protocols, self-image and health, food as identity, dietary changes, practitioner-client relationship, emotional root causes, integrative health, functional nutrition, practitioner defensiveness, normalizing failure, overcoming burnout, habit change strategies, self-judgment in healing, protocol adherence, client agency, empathetic listening, bridge foods, temporal discounting, self-soothing behaviors, practical coaching tools, referral to therapists Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Are you giving your complex concussion clients your absolute best care, or are you secretly running out of ideas when they hit a plateau? It's an uncomfortable truth: while every healthcare provider goes into practice genuinely wanting to help, caring deeply for your patients simply isn't enough when you reach the limits of your clinical knowledge. Far too often, when progress stalls, clinicians default to telling clients "it's just part of the concussion" or writing off lingering symptoms as purely psychosocial—leaving patients confused, frustrated, and stuck in treatment for months or years without actual recovery. When you settle for "good enough" care or miss hidden clinical blind spots, you risk breaking your patient's trust and holding them back from true healing. But hitting your clinical ceiling doesn't mean you can't push past it—by getting curious about your limitations, auditing your practice, and learning how to look deeper into complex, overlooked systems, you can step up to become the clinician your clients truly need. BY THE TIME YOU FINISH LISTENING, YOU'LL DISCOVER: Why compassion alone isn't enough to solve complex concussion cases—and how to identify when you've hit your clinical ceiling. The danger of writing off patient plateaus as "psychosocial" or "just concussion symptoms" instead of looking for deeper root causes. The major clinical blind spot most providers miss: how TBI impacts the central auditory processing system and impacts cognitive health. How to bridge the fragmentation gap across multidisciplinary care so PTs, OTs, Chiros, and Osteos can speak the same clinical language. Scroll down, hit play, and learn how to uncover your clinical blind spots and elevate your standard of concussion care today! Ready to raise your standard of care and stop hitting clinical ceilings? Join the waitlist for the revamped Concussion Nerds Fellowship 2.0! Doors open this fall for our brand-new cohort, limited to just 25 clinicians. Joining isn't a commitment—it simply gives you first priority to claim your seat before they're gone.

In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Can GLP-1 Agonists Elevate Lithium Levels?

Chronic inflammation is linked to a variety of health conditions, including heart disease, diabetes, arthritis, and other chronic illnesses. In this episode of Docs in a Pod, hosts Carmenn Miles and Dr. Brooke Mobley are joined by Magdalena Chavez, PA-C, from WellMed at Bedford to discuss the causes, symptoms, and management of chronic inflammation, along with practical tips for reducing inflammation, improving overall wellness, and supporting healthy aging. Tune in for expert insights on taking control of your long-term health.   Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT:  Austin (KLBJ 590 AM/99.7 FM)  Docs in a Pod also airs on Sundays in the following cities:  1:00-1:30 pm ET:  Tampa (860 AM/93.7FM)     

The new 2026 ACC Concise Clinical Guidance highlights why influenza, COVID-19, pneumococcal, RSV, and shingles vaccines should be considered an essential part of cardiovascular prevention. Strong evidence shows reductions in hospitalization, myocardial infarction, heart failure, stroke, and even mortality in selected populations. Prevention extends beyond statins and blood pressure control—it also includes timely immunization.

Physical activity is an effective component of care for people with chronic medical conditions. In this podcast, JAMA Insights author Alessio Bricca, PhD, University of Southern Denmark, discusses adaptable methods to promote physical activity in patients with chronic medical conditions with host Anne Rentoumis Cappola, MD, ScM. Related Content: Communicating With Patients About Physical Activity

Are you pricing your MedTech product based on evidence and value... or simply making an educated guess?Pricing is one of the most important commercial decisions you'll make, yet many MedTech founders spend years developing their product and only a few hours deciding what it's should cost. In this episode, Hakeem shares a practical five-step framework to help you understand your market, quantify your value, validate your pricing, and develop a pricing strategy that supports successful commercialisation and export.In this episode, you'll discover:Why competitor pricing should inform your thinking, but never determine your pricing strategy.How to assess the value your MedTech product creates and use it to justify your price.A practical framework for validating your pricing with clinicians, procurement teams, distributors, and customers before commercialisation and export.Listen now to learn how to price your MedTech product with confidence, strengthen your commercialisation strategy, and avoid costly pricing mistakes before entering new markets.If you need help with your pricing, message me on linkedin with the words "pricing supportThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.

For generations, doctors have had to make some of childbirth's most important decisions with incomplete information about how a baby is responding to labor. ARPA-H is funding research aimed at changing that by giving clinicians a clearer view of what's happening in real time. Here with more is Dr. Kate Arnold, Program Manager, Scalable Solutions at ARPA-H.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.

Clinician • Founder • Pain and Long COVID Specialist Understanding long COVID and Severe ME/CFS with Dr Robert Groysman. In the lead-up to Severe ME/CFS Day on August 8, Emerge Australia is proud to present a compelling episode of the Emerge Australia Imagine podcast series. Join CEO Anne Wilson in conversation with Dr Robert Groysman, a pioneering pain and long COVID specialist […]

Why Self-Insured Employers and Clinicians Keep Missing Each Other, With Suhas Gondi, MD. The Sleeping Giants of Healthcare: Why Employers and Clinicians Keep Missing Each Other. Episode 523. Dr. Suhas Gondi, MD, MBA, chief medical officer at Health Strategy and an attending physician at Massachusetts General Hospital, co-wrote a New England Journal of Medicine article — "A Sleeping Giant of Health Care Affordability—Self-Insured Employers" — because most clinicians, he found, have little idea a self-insured employer, not an insurance carrier, is the one actually paying for their patients' care. Talking with Stacey Richter, Dr. Gondi argues that self-insured employers and clinicians are both "sleeping giants," each holding real power over cost and access, who rarely communicate directly — leaving patients caught in the gap. WHAT YOU'LL LEARN ✅ Why Dr. Suhas Gondi and his NEJM co-author, Zirui Song, MD, PhD, wrote for clinicians who, they found, have little sense that a self-insured employer — not the carrier name on the card — actually pays for a patient's care ✅ How a GLP-1 prescription can get denied at the pharmacy counter even after a clinician verifies coverage, because the employer has quietly moved GLP-1 coverage exclusively through a single third-party prescribing and coaching vendor ✅ Why GLP-1 spending alone can push a self-insured employer's pharmacy costs up 9% to 20% in a year, and why the roughly eight-year payback period employers are counting on assumes patients stay adherent far longer than most actually do ✅ How oncology site-of-care steering — an employer declining to pay a roughly 40% premium for infusion at a hospital-owned center instead of a physician's office — can look to the patient and oncologist like a denied cancer drug ✅ Why Dr. Gondi says EHRs like Epic are built to optimize revenue for hospital-system customers, not to surface a lower-cost site of care for patients or plan sponsors ✅ Dr. Gondi's advice for closing the gap: clinicians and employers should communicate directly, especially before a coverage change lands on patients, rather than assuming direct contracting is the only fix WHY THIS MATTERS Roughly half to 60% of the US population has commercial insurance, and nearly three-quarters of large employers self-insure that coverage — yet most clinicians have no visibility into the plan-level decisions those employers make, and most employers have no channel to explain those decisions to the doctors whose patients are affected. Both sides, Dr. Gondi says, usually believe they're doing the right thing — covering the GLP-1, covering the cancer drug — and the patient still gets lost in between. Closing that gap doesn't require full direct contracting, he argues, just employers and local provider groups actually talking to each other before a coverage change lands on a patient, not after. MENTIONED IN THIS EPISODE Study: New England Journal of Medicine article, "A Sleeping Giant of Health Care Affordability—Self-Insured Employers," by Suhas Gondi, MD, MBA, and Zirui Song, MD, PhD EP406 with Lauren Vela: Apple Podcasts | Spotify | Other Apps EP519 with Lisa Rosenbaum, MD: Apple Podcasts | Spotify | Other Apps EP509 with Patrick Nelli: Apple Podcasts | Spotify | Other Apps EP494 with Sarah Emond: Apple Podcasts | Spotify | Other Apps EP501 with Ivana Krajcinovic, PhD: Apple Podcasts | Spotify | Other Apps EP468 with Matt McQuide: Apple Podcasts | Spotify | Other Apps Article: Acquired's episode on how Epic quietly powers American healthcare === LINKS ===

Luis Voloch, Co-Founder and CEO of Jimini Health, focuses on mental health through the Sage platform, which provides continuous AI support for patients while keeping clinicians informed and in control. The approach addresses the problem of patients turning to general-purpose AI for behavioral health support by offering a HIPAA-compliant, purpose-built alternative with proper safeguards and clinician supervision. The platform improves patient adherence to therapy and provides valuable information about progress between appointments, which is particularly important in mental health care where outcomes are non-linear and diagnostic precision is limited. Luis explains, "Right now, the AI healthcare environment is, I'd say, largely split when it comes to clinical AI between largely clinician-facing and back-office capabilities. So things like AI scribes and RCM tools and clinician coaching tools and products like that on one hand, with on the other hand, things that are primarily for patients. You may see things on the app store that are like AI therapists or products that are standalone for patients. And where Jimini stands is really as unifying both of these, where the core thesis for the company is that the right way to help patients and to build helpful clinical AI products is by integrating with the clinician as well, where the clinician has the ability to oversee what the AI is doing and to guide what the AI is doing."   "The company's belief is that we need to build purpose-built AIs for mental health that are HIPAA-compliant and safe, with all the right guardrails. And most importantly, where clinicians are in the loop and where the clinicians can oversee and guide what the AI is doing." "We primarily work with large behavioral health provider organizations interested in improving the quality of care they deliver. One specific big opportunity we bring is bridging the time between sessions so that patients have additional support. The core of the product is what we call Sage. Sage is an app that engages with patients in various ways, with the guidance of the clinician, so that Sage knows what is happening in the therapy sessions or whatever other appointments the patient is having. It is then able to follow the clinical priorities of the clinician when the clinician is not there, and Sage supports these patients on a daily basis." #JiminiHealth #MentalHealth #DigitalHealth #BehavioralHealth #AIinHealthcare #PatientEngagement #CareAdherence #Telehealth #HealthTech #AI #MentalHealth #PatientSafety jiminihealth.com Listen to the podcast here

Luis Voloch, Co-Founder and CEO of Jimini Health, focuses on mental health through the Sage platform, which provides continuous AI support for patients while keeping clinicians informed and in control. The approach addresses the problem of patients turning to general-purpose AI for behavioral health support by offering a HIPAA-compliant, purpose-built alternative with proper safeguards and clinician supervision. The platform improves patient adherence to therapy and provides valuable information about progress between appointments, which is particularly important in mental health care where outcomes are non-linear and diagnostic precision is limited. Luis explains, "Right now, the AI healthcare environment is, I'd say, largely split when it comes to clinical AI between largely clinician-facing and back-office capabilities. So things like AI scribes and RCM tools and clinician coaching tools and products like that on one hand, with on the other hand, things that are primarily for patients. You may see things on the app store that are like AI therapists or products that are standalone for patients. And where Jimini stands is really as unifying both of these, where the core thesis for the company is that the right way to help patients and to build helpful clinical AI products is by integrating with the clinician as well, where the clinician has the ability to oversee what the AI is doing and to guide what the AI is doing."   "The company's belief is that we need to build purpose-built AIs for mental health that are HIPAA-compliant and safe, with all the right guardrails. And most importantly, where clinicians are in the loop and where the clinicians can oversee and guide what the AI is doing." "We primarily work with large behavioral health provider organizations interested in improving the quality of care they deliver. One specific big opportunity we bring is bridging the time between sessions so that patients have additional support. The core of the product is what we call Sage. Sage is an app that engages with patients in various ways, with the guidance of the clinician, so that Sage knows what is happening in the therapy sessions or whatever other appointments the patient is having. It is then able to follow the clinical priorities of the clinician when the clinician is not there, and Sage supports these patients on a daily basis." #JiminiHealth #MentalHealth #DigitalHealth #BehavioralHealth #AIinHealthcare #PatientEngagement #CareAdherence #Telehealth #HealthTech #AI #MentalHealth #PatientSafety jiminihealth.com Download the transcript here

"It's not patients or profits, it's better health and healthcare." Gillian Sandler of Northwell Health sets the tone early in this episode, recorded live at Civic Health Forum. Moderator Sara Holoubek of Luminary Labs sits down with three leaders worki...

What are the skills AI will never replace and are you building your practice around them? In this episode of the IRH Clinician's Corner, Margaret Floyd Barry is joined by JJ Virgin for a conversation packed with insights for functional health practitioners looking to stand out and thrive in a rapidly changing world. From navigating the rise of AI and what it really means for health professionals, to doubling down on the irreplaceable human superpowers of coaching, discernment, and connection—this episode is all about finding your unique voice and impact in an increasingly crowded market.  JJ and Margaret break down actionable strategies for building trust, sharing vulnerability, and leveraging community, plus they offer a behind-the-scenes look at the upcoming, game-changing Mindshare Summit. Inside this episode, we explore: Why AI makes human connection, coaching, and discernment more valuable than ever The new practitioner superpowers that technology can't replicate How to become "niche famous" instead of chasing a massive audience The trusted authority framework for standing out in an AI-driven marketplace Why your contrarian conviction may be your greatest marketing advantage How vulnerability, proof, and real client stories build trust that AI-generated content never will The Clinician's Corner is brought to you by the Institute of Restorative Health: https://instituteofrestorativehealth.com/ Connect with IRH: Upcoming Event: PCOS has a new official name: Polyendocrine Metabolic Ovarian Syndrome. The science isn't new. Functional practitioners have understood the metabolic and hormonal complexity of these cases for years. The name just finally says so. On August 12th, Margaret Floyd Barry and Sara Fields are hosting a free live session on what this means for your practice. What shifts in how you assess and talk with female clients. What stays the same. Live Q&A at the end. Free. 60 minutes. Register here! Follow us on IG: https://www.instagram.com/instituteofrestorativehealth/ Join our email list here: https://instituteofrestorativehealth.com/join-our-email-list/ Connect with JJ Virgin: Website: http://www.thehbgc.com Instagram: https://www.instagram.com/healthbusinessgrowthcollective/ Facebook: https://www.facebook.com/mindsharecollaborative *Get your ticket now for JJ's last and best Mindshare Summit! Go to: https://tinyurl.com/thehbgc and use the code MARGARET500 to get $500 off Want to enter to get a FREE ticket to mindshare? Complete this Business Audit and email us yours at info@instituteofrestorativehealth.com and have a chance to be selected to win! Timestamps: 00:00 Podcast introduction and guest introduction 09:48 Hiring a coach for recovery 14:10 Navigating content marketing challenges 20:40 Storytelling advice with Lisa Nichols 23:20 Crafting a personal story for talks 29:29 PCOS name change discussion 33:09 Finding Your Unique Voice 38:49 Learning from case studies 44:05 Building a personal brand 51:54 Starting the RWS Mindshare 55:22 Transitioning Mindshare Event Model 59:27 Networking and business growth stories Guest bio:  JJ Virgin is a triple-board-certified nutrition expert, Fitness Hall of Famer, and 4-time New York Times bestselling author. JJ is a globally respected pioneer in health, business, and high-performance aging. She's the Chair of A4M's Profitable Practice Blueprint, Chief Metabolic Health Officer for Lindora Metabolic Health and Wellness, as well as the Nutrition & Fitness Speaker for Tony Robbins (Life Mastery and Unleash The Power), and the Founder of the Health Business Growth Collective (the most influential community of health entrepreneurs). She's also on the Advisory Board for the Integrative Healthcare Symposium and the host of the top-rated podcast Well Beyond 40, with over 22 million downloads, and has shared the stage with icons like Seth Godin, Gary Vaynerchuk, Dr. Mark Hyman, and more. Get ready to talk about mindset, metabolism, muscle, and how to age powerfully—this is going to be great! Keywords: functional health practitioners, clinical skills, chronic disease reversal, AI in healthcare, health business growth, Health Business Growth Collective, practitioner marketing, practitioner differentiation, niche branding, community building, client accountability, implementation strategies, practitioner vulnerability, storytelling in marketing, emotional intelligence, superpowers for health professionals, AI vs human connection, practitioner testimonials, building trust with clients, authoritative branding, overcoming failure, business mentorship, practice growth strategies, collaboration vs competition, personal branding, social media marketing, content creation, Mindshare Summit, scaling health businesses, practitioner success stories Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Have you ever wondered why some of your concussion clients suddenly hit a total plateau in their recovery, or why bringing up an insurance claim or lawsuit creates an immediate wall of tension in the room? Navigating concussion care is complex enough, but when you add insurance disputes, personal injury claims, and legal battles into the mix, the healing process often grinds to a halt. As clinicians, it is far too easy to fall into the trap of assuming a patient in litigation is "malingering," or to get caught in a chart-note tug-of-war that disrupts your care. On the flip side, clients are left feeling constantly judged, hypervigilant, and stuck in a system that forces them to fight for their limitations instead of celebrating their wins. This unspoken friction keeps the nervous system locked in fight-or-flight, leaving clinicians second-guessing their documentation and patients terrified that showing signs of healing will ruin their legal claim. But you don't have to choose between legal realities and clinical progress. By understanding how legal stress actively amplifies physical symptoms and creates a massive nocebo effect, you can protect the therapeutic alliance, chart with objective confidence, and help your clients heal—even while their case is ongoing. BY THE TIME YOU FINISH LISTENING, YOU'LL DISCOVER: The crucial difference between rare malingering (1–5%) and symptom magnification—and why baseline stress, not deception, is usually what drives amplified pain and dizziness. How the legal system's demand to "prove your disability" creates a nocebo effect that directly counteracts a brain-healing mindset. Practical documentation strategies for clinicians to stay accurate, keep your professional boundaries clear, and avoid getting caught in the legal crosshairs. How to guide clients through the profound nervous system reset and identity shift that happens once the heavy weight of a legal claim is finally lifted. Hit play to discover how to navigate the complex overlap of legal battles and concussion recovery so you can confidently guide your clients toward deep, lasting healing. Let's connect!   Instagram:  @natasha.wilch https://www.instagram.com/natasha.wilch/ Email: hello@natashawilch.com Website: https://www.natasha-wilch.com   Join the Clinician's Edge to have Your Weekly Taste of Neuro Wisdom  here: https://www.natashawilch.com/clinicians-edge   Join the Concussion Mini School and Membership! Get the support and resources you need for concussion recovery: https://www.natashawilch.com/concussionminischool

Joint pain doesn't have to slow you down. On this episode of Docs in a Pod, hosts Carmenn Miles and Dr. Brooke Mobley welcome Dr. Shelby Valero from WellMed at Division for an engaging discussion about osteoarthritis management. Learn what causes osteoarthritis, how it's diagnosed, and the latest approaches to treatment and symptom relief. Tune in for expert advice and practical tips to help you move with confidence.   Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT:  Austin (KLBJ 590 AM/99.7 FM)  Docs in a Pod also airs on Sundays in the following cities:  1:00-1:30 pm ET:  Tampa (860 AM/93.7FM)   

In this episode, Allison Schneider, Director of Applications at Aspen Valley Health, discusses how the organization evaluates AI-powered clinical decision support, the importance of clinician trust and governance, and lessons learned from implementing ClinicalKey AI to improve workflows while keeping patient care at the center.This episode is sponsored by Elsevier.

Why don't more doctors talk about death? Dr. Lydia Dugdale has been asking this question since she was a medical student. She is the Silberberg Professor of Medicine and directs the Center for Clinical Medical Ethics, and two books on how we die, including "The Lost Art of Dying." "Most medical professionals today are very unpracticed at talking to patients about their mortality," she says. Not only unpracticed, but even themselves afraid. In this bonus clip from Episode 232 with Macie Bridge, Dugdale traces the path from that early perplexity on the wards to the ars moriendi, the medieval art of dying, grounded in the idea that dying is part of living, so if you want to die well you have to live well. Lydia comments on the emergence of palliative care and the way it let physicians hand conversations about death to specialists; the doctor who inherited the priest's old place at the threshold between life and death; the death anxiety clinicians carry without examining; virtue as preparation for dying, and community as the other half of living well; the unrepresented patients of New York City who die alone; and a grumpy old man, hospitalized for 20 years, who wept when she read aloud what she had written about him. Episode Highlights “Most medical professionals today are very unpracticed at talking to patients about their mortality.” “we are really the intermediaries between life and death, I'm not saying we're priests, but that used to be the role of the priest. And so it is now the role of the physician. “If you want to die well, you have to live well.” We have to be all in or we end up like all of these patients here in New York City who have no one that I can reach out to as they're dying. “He started weeping and he said, someone finally saw me. Someone finally saw me. I've been in this hospital for 20 years and I didn't think anyone ever saw me.” About Lydia Dugdale Lydia Dugdale is a physician and medical ethicist who has spent fifteen years asking why medicine finds death so hard to talk about. She is the Silberberg Professor of Medicine at Columbia, directs the Columbia Center for Clinical Medical Ethics, and co-directs clinical ethics at NewYork-Presbyterian Milstein Hospital, where she still sees patients. She edited "Dying in the Twenty-First Century" and wrote "The Lost Art of Dying," a modern ars moriendi. She trained at the University of Chicago and Yale-New Haven Hospital, holds a master's in ethics from Yale Divinity School, and in 2025 founded the nonprofit Heal the Nation. Helpful Links and Resources “Dying Alone,” the full Episode 232 with Lydia Dugdale and Macie Bridge: https://faith.yale.edu/media/dying-alone Lydia Dugdale's website: https://lydiadugdale.com/ The Lost Art of Dying: Reviving Forgotten Wisdom, Lydia Dugdale's book: https://www.harpercollins.com/products/the-lost-art-of-dying-ls-dugdale Dying in the Twenty-First Century, edited by Lydia Dugdale: https://mitpress.mit.edu/9780262534598/dying-in-the-twenty-first-century/ Columbia Center for Clinical Medical Ethics, which Dugdale directs: https://www.vagelos.columbia.edu/departments-centers/columbia-center-clinical-medical-ethics Columbia Center for Clinical Medical Ethics on X: https://x.com/columbia_ccme Ars moriendi, the medieval art of dying, at the Morgan Library and Museum: https://www.themorgan.org/blog/new-acquisition-ars-moriendi-blockbook Ars moriendi block book, 1475, at the Library of Congress: https://www.loc.gov/item/2021666798/ Lydia Dugdale at the Yale Center for Faith and Culture: https://faith.yale.edu/people/lydia-dugdale-md Show Notes Death anxiety in medicine Why doctors avoid frank conversations about mortality Palliative care's arrival as a discipline, and what it made possible Real gains in symptom relief for the sick and the dying The unintended cost: death conversations outsourced to specialists Clinicians as intermediaries between life and death The priest's old place at the threshold, now the physician's Nurses at the bedside, doctors calling the shots on treatment Existential questions physicians have never worked through A colleague who would never tell a patient they were dying, out of her own fear of death Digging into how other times and places handled mortality Ars moriendi: the medieval genre on the preparation for death Illustrated editions made for people who could not read Fifteen years and two books spent reviving the art of dying Living well as the precondition of dying well Virtue as preparation: hope, patience, joy against bitterness and despair The role of community in dying well New York's unrepresented patients, dying alone A reader estranged from his adult children who committed to years of repair after the book Relationship as ongoing work: rupture, forgiveness, iron sharpening iron A long-hospitalized patient nobody wanted assigned to their team Modeling care for young doctors, and being verbally destroyed in front of them Loneliness of the neighbor, the colleague, the checkout person Practice as the only way to get better at it #ForTheLifeOfTheWorld #LydiaDugdale #TheLostArtOfDying #ArsMoriendi #MedicalEthics #DyingWell #Loneliness #EndOfLifeCare Production Notes This podcast featured Lydia Dugdale Edited and Produced by Evan Rosa Hosted by Evan Rosa Production Assistance by Noah Senthil A Production of the Yale Center for Faith & Culture at Yale Divinity School https://faith.yale.edu/about Support For the Life of the World podcast by giving to the Yale Center for Faith & Culture: https://faith.yale.edu/give

What do clinicians actually want before they'll adopt your MedTech product?Many MedTech founders focus on product features, clinical evidence, and regulatory approval, believing these alone will drive adoption. But clinicians evaluate new technologies through a very different lens. In this episode, Hakeem shares the five biggest lessons from his conversation with Dr Tangwan Azorfor, giving you a clinician's perspective on what really influences adoption and how you can better align your commercialisation strategy with the realities of clinical practice.In this episode, you'll discover:Why improving patient care is the first thing clinicians look for when evaluating a new MedTech product.How workflow, training, and real-world clinical experience influence adoption more than many founders realise.Five practical lessons to help you position your MedTech product for stronger clinical adoption from a clinician's perspective.Listen now to understand what clinicians really want before adopting a new MedTech product and learn how to apply these insights to improve adoption and commercial success.Book a 30min Healthcare Export Accelerator discovery callMessage me via DM on LinkedinThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.

Send us Fan MailDr. Lauren Hall, a new physician with UnityPoint Clinic Family Medicine - Mount Vernon, joins Dr. Arnold to talk about her background, clinical and personal interests, what led her to UnityPoint Health and much more.If you would like to schedule an appointment with Dr. Hall, call UnityPoint Clinic Family Medicine – Mount Vernon at (319) 895-8841 . This is another episode in a segment on the podcast called "New Clinician Spotlight." In these episodes, Dr. Arnold will sit down with new clinicians at UnityPoint Health - Cedar Rapids and get to know them as a clinician and as a person.If you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

"It's not a behavioral issue; it's a regulation issue." When we stop viewing neurodivergent children through the lens of pathology and start listening to their nervous systems, we realize they aren't broken, they're inviting us to awaken. In this episode of our Clinicians Series, where we go behind the therapy door to explore the strategies and approaches that truly transform mental health—host Sharlee Dixon welcomes back Dr. Nicole Dolan. Nicole is a writer, former clinician, and intuitive coach whose work bridges depth psychology, neuroscience, spirituality, and her own lived experience as a mother. Her forthcoming book, “The Art of Chaos”, explores how her world fell apart and how she discovered meaning, resilience, and healing within the mess of trauma, motherhood, and raising a neurodivergent child. Drawing from her background as a clinical director and her transition into holistic family coaching, Nicole helps parents uncover hidden patterns, heal generational wounds, and find strength through conscious parenting. Together, they explore how Nicole bridges clinical psychology, neuroscience, and spirituality to support neurodivergent children and their families. They uncover what traditional clinical models miss, how parents can regulate their own nervous systems to foster deep healing, and how clinicians can develop the skills needed to work effectively with neurodivergent family systems. Join us for an enlightening conversation about moving past boxes and labels toward wholeness, authentic connection, and true systemic healing.   For more information about Dr. Nicole Dolan, please visit: https://drnicoledolan.com For more information about Sacred Path Holistic Therapy (sliding-scale therapists), please visit: https://sacredpathholistictherapy.com If you would like to work with Dr. Nicole Dolan, please visit: https://sacredpathholistictherapy.com/work-with-dr-nicole-dolan/ For more information about “In An Unspoken Voice: How the Body Releases Trauma and Restore Goodness”, by Peter Levine, PhD, please visit: https://www.northatlanticbooks.com/shop/in-an-unspoken-voice/ Connect with Dr. Nicole Dolan on Instagram at: https://www.instagram.com/drnicoledolan/ Connect with Dr. Nicole Dolan on Linkedin at: https://www.linkedin.com/in/nicole-dolan-phd-lmft-338771b1/

On this episode of the Vet Blast Podcast presented by dvm360,  host Adam Christman, DVM, MBA sits down with Ori Stollar, M.Sc., DVM, DACVB, to break down the top five stress behaviors every clinician and technician should be able to spot in dogs and cats — including one that's often mistaken for a calm pet.

What Nobody Is Telling You About Peptide Stacks and GLP-1s Peptides are everywhere. Stacks are trending. Influencers are dosing on camera. Clinicians are ordering compounds off websites. And somewhere in all of it, the actual science of how these molecules work — and what can go wrong when you combine them without testing — is getting completely lost. Dr. Terri sits back down with Jim LaValle, RPh, CCN, for a no-nonsense conversation on the state of the peptide and GLP-1 landscape in 2025. They cover peptide stacking, why combining untested compounds in a single vial is not precision medicine, the black market GLP-1 problem, what retatrutide actually is and why so many people are injecting a version of it that has never been tested for human safety, and what's happening to patients — and clinicians — who cut corners. They also go deep on GLP-1s done right: why 30% of Dr. Terri's patients are on one, why the ones who thrive are the ones who do the work, and why a thinner person can still be metabolically sicker than before they started. If you or someone you love is using peptides or GLP-1s — or thinking about it — this is the episode to share. What you'll discover: Why peptide stacks sound like precision medicine but are actually dartboard medicine without stability and efficacy data [04:02] What "research use only" and "physician use only" actually means on a label — and why injecting it is a gamble [09:34] The regulatory reality: why rogue labs are giving the FDA the ammunition to shut down all compounding [10:20] Retatrutide: what the three-mechanism GLP-1 actually is, why it's not legally available yet, and what patients are actually injecting when they think they're on it [25:31] Dr. Terri's clinical red flag: three postmenopausal patients on black market retatrutide all presenting with unexpected spotting [28:04] Why GLP-1s done wrong are creating scurvy, bone loss, hair loss, and skinny fat — and what done right actually looks like [33:14] How to protect gut integrity, lean mass, and metabolic rate while on a GLP-1 [32:48] Why food noise comes back every time the dose drops — and how addressing sympathetic dominance may be the real fix [38:07] The full circle: GLP-1s, nervous system, dopamine, and why stress is what created the craving in the first place [38:07] A tool used wrong is still a tool used wrong. Do this right or don't do it. The Dr. Terri Show is presented by EVEXIAS Health Solutions.Learn more and find a provider near you at evexias.com Connect with Dr. Terri:

What if decluttering isn't about organization, but about removing barriers to healing? In this episode of the IRH Clinician's Corner, Margaret Floyd Barry is joined by Heather Aardema, founder of the School of Living Lighter, to delve into the often-overlooked but profoundly impactful connection between clutter and health. Together, Margaret Floyd Barry and Heather Ardema discuss why clutter is more than a matter of organization, it's a health issue that affects our nervous systems, our energy, and even our capacity to heal. They provide a new, compassionate definition of clutter as "anything that gets between where you are and where you want to be" and share practical strategies to address environmental and internal barriers to well-being. Inside this episode, we explore: Why clutter is more than a lifestyle issue—it can become a genuine health concern Heather's powerful journey through severe mold illness and what it taught her about healing A new definition of clutter: anything that gets between where you are and where you want to be How physical, mental, and emotional clutter all contribute to nervous system overload Why practitioners must honestly address environmental triggers before focusing on supplements and protocols How regulating the nervous system makes lasting decluttering—and healing—possible The Clinician's Corner is brought to you by the Institute of Restorative Health: https://instituteofrestorativehealth.com/ Connect with IRH: Upcoming Event: PCOS has a new official name: Polyendocrine Metabolic Ovarian Syndrome. The science isn't new. Functional practitioners have understood the metabolic and hormonal complexity of these cases for years. The name just finally says so. On August 12th, Margaret Floyd Barry and Sara Fields are hosting a free live session on what this means for your practice. What shifts in how you assess and talk with female clients. What stays the same. Live Q&A at the end. Free. 60 minutes. Register here! Follow us on IG: https://www.instagram.com/instituteofrestorativehealth/ Join our email list here: https://instituteofrestorativehealth.com/join-our-email-list/ Connect with Heather Aardema: Website: https://www.schooloflivinglighter.com/ YouTube: https://www.youtube.com/@heatheraardema Instagram: https://www.instagram.com/heatheraardema/ Facebook: https://www.facebook.com/schooloflivinglighter Check out Heather's DIY Decluttering Course, called Less. Regularly $397, only $197 with coupon LIGHTER. https://www.schooloflivinglighter.com/less Timestamps:  00:00 Heather's journey to decluttering expert 07:21 Severe health effects from mold 14:33 Challenges of mold remediation 16:41 Discussing the concept of clutter 24:52 Difficult client conversations 29:20 Dealing with mold-related health issues 33:56 Deeper meaning behind clutter 41:15 Sponsor acknowledgments and tools 45:15 Exploring the impact of clutter 48:59 Realizing the emotional side of clutter 58:09 Dealing with parents' belongings 59:10 Balancing empathy in health coaching 01:05:42 Episode closing and acknowledgments Guest bio:  Heather Aardema is the founder of the School of Living Lighter. She helps people understand how physical, mental, emotional, and environmental clutter affect the nervous system, energy, and everyday health. Through a mind-body-home approach, Heather teaches practical ways to reduce overwhelm, restore clarity, and create environments that support healing, especially during seasons of transition, chronic stress, or physical upheaval in the home. Keywords: functional health, clutter, mold toxicity, decluttering, nervous system regulation, chronic disease, environmental health, mind-body-home approach, chronic stress, health coaching, autoimmune disease, rheumatoid arthritis, paleo diet, body clutter, mind clutter, home organization, sentimental items, mold remediation, detoxification, supplements, toxic mold symptoms, self-worth, emotional attachment to belongings, boundaries, nervous system safety, family dynamics, practitioner-client communication, chronic illness, grief and loss, individualized approaches, chronic health conditions Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Gene Zannetti talks with Kyle Kiss and Troy Heilmann about the Garden State Wrestling Prospect Camp coming August 12-15 at Saint Joseph's Montclair, featuring nearly 30 college programs and top clinicians including national champions Darian Cruz and Troy Nicholson, why the camp is designed to help wrestlers at every level understand the recruiting process even if their perfect school isn't in the room, and the message both Kyle and Troy want to leave with every wrestler: use this sport as a vehicle to open doors not just for yourself but for your children.Timestamps:1:28 - Camp details: August 12-15 at Saint Joe's Montclair, 30 boys colleges committed2:38 - Clinicians span Ivy League, service academy, Big Ten, and ACC backgrounds3:45 - Even if your perfect school isn't there, you'll understand the process better9:50 - NIL breakdown: how the money actually works and why it's getting tighter12:43 - Using wrestling as a vehicle13:09 - Wrestling as a vehicle — doors it opens not just for you but for your children

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Have you ever stopped to ask yourself how clinicians really decide whether to adopt a new MedTech product?Understanding how clinicians make decisions is one of the most overlooked aspects of MedTech commercialisation. Product features and clinical evidence matter, but they're only part of the decision. In this episode, Hakeem explores what really influences clinician adoption, from patient outcomes and workflow to trust, ease of use, and perceived value, helping MedTech founders better prepare their products for commercial success.In this episode, you'll discover:How clinicians really evaluate whether to adopt a new MedTech product.The key factors that influence clinical adoption beyond evidence alone.Practical insights to strengthen your commercialisation strategy and improve MedTech adoption.Listen now to discover how clinicians make adoption decisions and learn how to position your MedTech product for stronger commercial success and wider clinical adoption.Book a 30min Healthcare Export Accelerator discovery callMessage me via DM on LinkedinThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.